What is the current India Diabetes Drugs and Devices Market size?

November 2022: AstraZeneca India gets approval to market the anti-diabetes drug Dapagliflozin. The company said it had received approval from the Central Drugs Standard Control Organization (CDCSCO) for the drug indicated for diabetes patients with chronic kidney disease (CKD).
March 2022: Medtronic India launched the MiniMed 780G, a next-generation closed-loop insulin pump system. The MiniMed 780G system is a next-generation closed-loop insulin pump system for treating type-1 diabetes in people aged 7-80 years.

The India Diabetes Drugs and Devices Market is projected to register a CAGR of greater than 3% during the forecast period (2024-2029) Read More

Who are the key players in India Diabetes Drugs and Devices Market?

Medtronics , Roche, NovoNordisk, Sanofi and Omnipod are the major companies operating in the India Diabetes Drugs and Devices Market. Read More

What years does this India Diabetes Drugs and Devices Market cover?

The report covers the India Diabetes Drugs and Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the India Diabetes Drugs and Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

India Diabetes Drugs and Devices Market Share

Statistics for the 2023 & 2024 India Diabetes Drugs and Devices market share, created by Mordor Intelligence™ Industry Reports. India Diabetes Drugs and Devices share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of India Diabetes Drugs and Devices Industry

Manufacturers have always innovated to outlive in the industry. Big firms as an example Abbott and Medtronic have made abundant mergers, acquisitions, and partnerships to attain industry dominance whereas adhering to biological development techniques. The manufacturers of insulin delivery tools are spending substantial amounts on the R&D of the tools. For example, Novo Nordisk partnered with Abbott Diabetes Care, that may additionally aid to enable insulin statistics to be shared between Novo Nordisk-connected insulin pens and digital fitness trappings well qualified to the FreeStyle Libre portfolio of cosmetics.